StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) stock

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.87+1.77 (+6.30%)

Close on Nov 17, 2026Market cap $1.46BP/E –Yield –

UroGen Pharma gross margin

Gross margin is gross profit as a percentage of revenue.

UroGen Pharma's gross margin for the twelve months ending Jun 30, 2026 was 90.8%. For fiscal 2025 it was 88.7%, against 90.2% the year before. The highest annual figure on record is 100.0% in fiscal 2019.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202588.7%−1.5
FY2024Dec 31, 202490.2%+1.5
FY2023Dec 31, 202388.7%+0.6
FY2022Dec 31, 202288.1%−1.2
FY2021Dec 31, 202189.3%−2.2
FY2020Dec 31, 202091.4%−8.6
FY2019Dec 31, 2019100.0%+159.8
FY2018Dec 31, 2018-59.8%−152.5
FY2017Dec 31, 201792.6%−7.2
FY2016Dec 31, 201699.8%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202690.9%+5.6
Q1 FY2026Mar 31, 202691.9%+3.4
Q4 FY2025Dec 31, 202591.3%+1.4
Q3 FY2025Sep 30, 202588.1%−2.2
Q2 FY2025Jun 30, 202585.3%−4.5
Q1 FY2025Mar 31, 202588.5%−2.3
Q4 FY2024Dec 31, 202489.9%−0.3
Q3 FY2024Sep 30, 202490.3%+1.6
Q2 FY2024Jun 30, 202489.8%+1.4
Q1 FY2024Mar 31, 202490.8%+4.0
Q4 FY2023Dec 31, 202390.3%+2.8
Q3 FY2023Sep 30, 202388.6%+1.2
Q2 FY2023Jun 30, 202388.4%−0.4
Q1 FY2023Mar 31, 202386.8%−1.9
Q4 FY2022Dec 31, 202287.5%−2.7
Q3 FY2022Sep 30, 202287.5%−1.6
Q2 FY2022Jun 30, 202288.9%−0.2
Q1 FY2022Mar 31, 202288.8%+0.7
Q4 FY2021Dec 31, 202190.2%−1.6
Q3 FY2021Sep 30, 202189.0%−2.0
Q2 FY2021Jun 30, 202189.1%+2.0
Q1 FY2021Mar 31, 202188.0%−12.0
Q4 FY2020Dec 31, 202091.8%+364.6
Q3 FY2020Sep 30, 202091.1%+78.4
Q2 FY2020Jun 30, 202087.1%+76.5
Q2 FY2019Jun 30, 2019100.0%+87.8
Q3 FY2018Sep 30, 2018-272.8%−369.0
Q2 FY2018Jun 30, 201812.6%+7.4
Q1 FY2018Mar 31, 201810.6%–
Q4 FY2017Dec 31, 201712.2%–
Q3 FY2017Sep 30, 201796.2%–
Q1 FY2017Mar 31, 20175.3%–

More UroGen Pharma figures

See a number that looks wrong?